COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,786 Articles (22,946 medRxiv, 8,840 bioRxiv)

Most recent first Previous |  Page 3062: Articles 30611-30620  | Next

Amantadine disrupts lysosomal gene expression; potential therapy for COVID19
Smieszek, S., Przychodzen, B., Polymeropoulos, M. H.
10.1101/2020.04.05.026187 — Posted: 2020-04-05 Discussion: Onsite
Indomethacin has a potent antiviral activity against SARS CoV-2 in vitro and canine coronavirus in vivo
Xu, T., Gao, X., Wu, Z., Selinger, D. W., Zhou, Z.
10.1101/2020.04.01.017624 — Posted: 2020-04-05 Discussion: Onsite
LY6E Restricts the Entry of Human Coronaviruses, including the currently pandemic SARS-CoV-2
Zhao, X., Zheng, S., Chen, D., Zheng, M., Li, X., Li, G., Lin, H., Chang, J., Zeng, H., Guo, J.-T.
10.1101/2020.04.02.021469 — Posted: 2020-04-05
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
Fintelman-Rodrigues, N., Sacramento, C. Q., Ribeiro Lima, C., Souza da Silva, F., Ferreira, A., Mattos, M., de Freitas, C. S., Cardoso Soares, V., da Silva Gomes Dias, S., Temerozo, J. R., Miranda, M., Matos, A. R., Bozza, F. A., Carels, N., Roberto Alves, C., Siqueira, M. M., Bozza, P. T., Souza, T. M. L.
10.1101/2020.04.04.020925 — Posted: 2020-04-05 Discussion: Onsite | Offsite
Increasing testing throughput and case detection with a pooled-sample Bayesian approach in the context of COVID-19
Noriega, R., Samore, M.
10.1101/2020.04.03.024216 — Posted: 2020-04-05
Rapid community-driven development of a SARS-CoV-2 tissue simulator
Wang, Y., Heiland, R., Craig, M., Davis, C. L., Ford Versypt, A. N., Jenner, A., Ozik, J., Collier, N., Cockrell, C., Becker, A., An, G., Glazier, J. A., Narayanan, A., Smith, A. M., Macklin, P.
10.1101/2020.04.02.019075 — Posted: 2020-04-05 Discussion: Onsite
One-step RNA extraction for RT-qPCR detection of 2019-nCoV
Sentmanat, M., Kouranova, E., Cui, X.
10.1101/2020.04.02.022384 — Posted: 2020-04-05
Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection
Mantlo, E. K., Bukreyeva, N., Maruyama, J., Paessler, S., Huang, C.
10.1101/2020.04.02.022764 — Posted: 2020-04-05 Discussion: Onsite | Offsite
SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles
Bojkova, D., McGreig, J. E., McLaughlin, K.-M., Masterson, S. G., Widera, M., Kraehling, V., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J. N.
10.1101/2020.04.03.024257 — Posted: 2020-04-05 Discussion: Offsite
Prediction and Evolution of B Cell Epitopes of Surface Protein in SARS-CoV-2
Lon, J. R., Bai, Y., Zhong, B., Cai, F., Du, H.
10.1101/2020.04.03.022723 — Posted: 2020-04-05 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).